TNK2 and chronic myelomonocytic leukemia: Indeed, Ack1 is an important therapeutic target for acute myeloid leukemia (AML) with constitutively active NRAS mutations [76,77] and in chronic myelomonocytic leukemia since these mutations are sensitive to inhibitors of Ack1 [58,78].